- Home
- EPSM vs BEAT Comparison
EPSM vs BEAT Comparison
Compare EPSM & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | BEAT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | N/A | 16 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 58.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EPSM | BEAT |
|---|---|---|
| Price | $2.01 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 113.0K | ★ 473.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.54 |
| 52 Week High | $155.00 | $4.00 |
Technical Indicators
Market Signals| Indicator | EPSM | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 42.69 |
| Support Level | $1.65 | $1.33 |
| Resistance Level | $2.35 | $1.82 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 42.52 | 14.32 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.